



ePAGS bi-annual meeting

EHA 2026 - Stockholm
12 June 2026

- ToR Update on the signature
- Some relevant actions with ePAGs
- Upcoming actions (education and patient versions of guidelines)
- Update on the HLM by Mar
- Engagement of ePAGs in ERN Scientific & strategic Committee
- Free debate



ToR Update on the signature

Missing ePAGs:

- **Jan Geissler (Leukemia Patient Advocates Foundation):** Jan is no longer active in the role and has decided to step down from his position. In line with the ToR, he is required to identify a new ePAG representative to succeed him and complete the replacement process according to the established ToR procedure.
- **Ananda Plate (Myeloma Patients Europe):** Ananda has not been active for over a year and has now been replaced by Monica, who will sign the ToR on behalf of Myeloma Patients Europe.



MPE ePAGs representation update



Monica Racovita

Myeloma Patients Europe

- PhD in Global Social Sciences from Doshisha University, Japan
- Comes from Romania and currently resides in UK
- Worked on science and health policy issues in academia, international development or consultancy in Italy, Austria and the UK.
- Access and Policy Manager at MPE



Educational activities: patients

EHC-ERN-EuroBloodNet Topic on Focus: Ageing well with rare bleeding disorders, for patients and their families



Marius Tanase

European Haemophilia Consortium (EHC)

•Session 1: Strong at Any Age - Redefining Frailty Together

- Date: 22 January 2026
- Speakers: Dr William McKeown (EHC Steering Committee, Queen's University Belfast, UK) and Prof Susie Shapiro (Oxford University Hospital, UK).

•Session 2: Von Willebrand factor and von Willebrand Disease in ageing: mechanisms, evolving phenotypes, and clinical implications

- Date: 09 March 2026
- Speakers: Prof Flora Peyvandi (Foundation IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy) and Cathy Verbraeken (EHC VWD Committee)

•Session 3: Bleeding Disorders and Ageing - Shall I bleed less with age?

- Date : 27 April 2026
- Speakers : Prof Yesim Dargaud (Hôpital cardiologique Louis-Pradel de Lyon, France), Prof Sophie Susen (CHU de Lille, France) and Dr William McKeown (EHC Steering Committee, Queen's University Belfast, UK).

•Session 4: Cardiovascular Issues and other comorbidities

- Date: 18 May 2026
- Speakers: Prof Roger Schutgens (University Medical Center Utrecht, Germany), Prof Bruna Gigante (Karolinska University Hospital, Stockholm, Sweden) and Prof Alison Dougall (Dublin Dental University Hospital, Ireland).

Manuscript prepared for submission

Co-branded with ERN GUARD Heart



Ongoing activities patients


Topic on Focus: EU Health Policy for patients organizations



FITHAD
FONDAZIONE ITALIANA TALASSEMIA E DREPANOCITOSI
LEONARDO GIAMBRONE



**European
Reference
Network**
for rare or low prevalence
complex diseases
Network
Hematological
Diseases (ERN EuroBloodNet)



Angelo Loris Brunetta

Thalassaemia International Federation

1. Spazio Europeo dei Dati Sanitari (EHDS)

→ Registri, dati dei pazienti, aspetti etico-legali della governance

Relatore: Iñigo de Miguel (esperto legale, collaboratore ERN-EuroBloodNet)

2. Regolamento sulle Sostanze di Origine Umana (SoHO)

→ Sangue, plasma, sistemi di emovigilanza, raccolta e distribuzione

Relatrice : Gabriella Peluso Cassese

3. Valutazione delle Tecnologie Sanitarie (HTA)

→ Prezzi e rimborso dei farmaci dopo l'autorizzazione dell'EC

Relatrice : Anna Ponzianelli

4. Nuova Legislazione Farmaceutica Europea

→ Processo di approvazione, accesso equo, incentivi, terapie avanzate

Relatore (da confermare): **to be confirmed**

Upcoming: Repeating same webinar series in English for a wider audience



Upcoming activities for patients - Autumn 2026



edu
EDU | BloodAcademy

Topic on Focus: TTP

Online comprehensive educational program on Thrombotic Thrombocytopenic Purpura (TTP) for Patients.

(Information coming soon)



Two other educational webinars for patients:

- Webinar for patients on VWD in Collaboration with EHC on September 10th: **Updated global prevalence and ethnic diversity of von Willebrand disease based on population genetics analysis.**
- Webinar on MaTCL for patients (Imune T- ME project experts) in 2027

Program coordinators: Flora Peyvandi and Paul Coppo

ePAG: Ioana Tadarova

7 modules: 1 module/ month starting October 2026 until April 2027



Designing Patient-Centered Care

Patient Journeys from Educational Programs, pilot of
von Willebrand Disease

Patient Versions of Guidelines, pilot of Burkitt
Lymphoma





Patient Journeys



- A visual or narrative tool that maps the typical steps a patient takes through a disease: from first symptoms to diagnosis, treatment, daily management, and long-term care
- Includes clinical, emotional, and social experiences
- Developed with patients, caregivers, and clinicians, highlighting needs, barriers, and goals

Patient Versions of Guidelines



- A simplified, accessible version of evidence-based clinical guidelines
- Written for patients, not for doctors
- Explains e.g.: What care to expect, which options exist
- Always aligned with official recommendations
- Ideally, it should be developed with patients, but this is not yet standard practice. Within the ERN, however, it has been developed in collaboration with patients.



Preparation: A Patient Journey Built *from* Educational Program

1. The educational program was designed following the structure of a **patient journey**, all critical health stages for vWD

2. Each webinar tackled a specific stage, identified through collaborative work with: **Patient support groups** (to reflect lived experiences and needs) **Expert health professionals** (to align with clinical pathways and guidelines)

Outcome:

The program naturally evolved into a structured patient journey, with learning objectives and take-home messages mirroring real-life care phases





ERN-EuroBloodNet Topic on Focus: von ...

by ERN-EuroBloodNet's EDU

Playlist • Public • 13 videos • 26 views

ERN-EuroBloodNet "Topic on Focus: von Willebrand Disease (VWD) for patient organizations and health ...more

▶ Play all



Sort

All

Videos

Shorts



ERN-EuroBloodNet Topic on Focus on VWD - VWD is not hemophilia

ERN-EuroBloodNet's EDU • 93 views • 4 months ago



ERN-EuroBloodNet Topic on Focus on VWD - Genetics of VWD

ERN-EuroBloodNet's EDU • 77 views • 4 months ago



ERN-EuroBloodNet Topic on Focus on VWD - Type doesn't define...

ERN-EuroBloodNet's EDU • 121 views • 4 months ago



ERN-EuroBloodNet Topic on Focus on VWD - People with VWD ble...

ERN-EuroBloodNet's EDU • 92 views • 4 months ago



European
von Willebrand Disease
Community



European
Reference
Network

Hematological
Diseases (ERN EuroBloodNet)



Funded by
the European Union



Phases 1 & 2: Mapping and Structure

1. Extract “**take-home messages**” from each webinar
2. Generate and **cluster key concepts** by disease stage: *Awareness, Diagnosis, Psychosocial Adaptation, Daily Management, Female Life Stages, Emergency, Ageing*
3. **Tag each concept** by: Type (clinical, psychosocial, etc.), *Target population, Stakeholders involved*
4. **Steering Committee validated the journey**
5. **Final format** (video, flyer, interactive map...)

Key aspect:

- ✓ Validation of clusters/tags by session speakers (experts via ERN + patients via EHC)
- ✓ Literature review planned for benchmarking with other chronic diseases
- ✓ ERNs expert centers and National Patients Organisations focusing on vWD will be added in the journey



Patient Versions of Guidelines

Pilot of Burkitt Lymphoma

Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet

[Vincent Ribrag, MD](#)  ^{a,b}  · [Prof Dominique Bron, MD, PhD](#) ^c · [Grzegorz Rymkiewicz, MD, PhD](#) ^d ·
[Prof Dieter Hoelzer, MD, PhD](#) ^f · [Judit Jørgensen, MD](#) ^g · [Aythami de Armas-Castellano, BS](#) ^h ·
[Maria Trujillo-Martín, PhD](#) ^{h,i} · [Prof Pierre Fenaux, MD, PhD](#) ^{j,k} · [Prof Luca Malcovati, MD, PhD](#) ^{l,m} ·
[Natacha Bolaños](#) ⁿ · [Prof Josep-Maria Ribera, MD, PhD](#) ^o · [Prof Charles Herbaux, MD, PhD](#) ^p ·
[Clémentine Sarkozy, MD, PhD](#) ^q · [Prof Pier Luigi Zinzani, MD, PhD](#) ^r · [Prof Jan Walewski, MD, PhD](#) ^e ·
[Prof Martine E D Chamuleau, MD](#) ^s [Show less](#)

 | Collaborative Planning & Patient-Centered Drafting

Steering Committee: From guideline authors identify 4 health professionals, Patient advocates

Lived Experience Council: Identify patients with Burkitt Lymphoma Ensuring EU geographical representation

Begin Co-Creation Process

- Identify key patient-relevant recommendations
- Simplify complex content; use plain language
- Consider FAQ/narrative style, short paragraphs, bullets
- Conduct feedback sessions with patient advocates



Validation, Accessibility & Sustainable Impact

Validate the Draft

- Clinical accuracy check
- Readability & relevance reviewed by patient advocates
- Optional: testing with external patient group

Ensure Accessibility

- Visual aids, icons, accessible fonts
- Screen reader compatibility, translations
- Decide the format & translate the document in different languages

Dissemination Strategy

- Share via websites, clinics, social media, patient organisations
- Include a link to the full clinical guideline
- For booster CBH: Include a list of expert centers in Europe via ERN, and a list of Patients organisations in Europe via Lymphoma Coalition



www.eurobloodnet.eu



@ERNEuroBloodNet



[eurobloodnet-european-reference-network-on-rare-hematological-diseases](https://www.linkedin.com/company/eurobloodnet-european-reference-network-on-rare-hematological-diseases)



Eurobloodnet - European Reference Network on Rare Hematological Diseases



ERN-EuroBloodNet's EDUcational Youtube channel



European
Reference
Network

Hematological
Diseases (ERN EuroBloodNet)

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.



Funded by
the European Union



PVGs: Challenges and Recommendations:

Barriers

- Limited resources (time & funding)
- Lack of standardized methodologies
- Access to a clear, high-quality clinical guideline to base the PVG
- Difficulties in reaching consensus among stakeholders.

**Developped & Endorsed by
the ERN-EuroBloodNet**

**Easy accessibility and right
to develop PVGs**

dissemination and implementation of
PVGs to reach the target patient
population.

Patient Journeys from Educational Programs

Pilot of von Willebrand Disease



European
von Willebrand Disease
Community



Steering Committee:



Mariangela Pelligrini
ERN-EuroBloodNet



Sophie Susen
CHU de Lille, France



Jeroen Eikenboom
Leiden University Medical
Center, the Netherlands



Flora Peyvandi
Foundation IRCCS Ca'Granda
Ospedale Maggiore Policlinico,
Milan, Italy



Daria Camilli
European Haemophilia
Consortium (EHC)



VWD Committee
European Haemophilia
Consortium (EHC)



Marius Tanase
ERN-EuroBloodNet ePAG,
European Haemophilia
Consortium (EHC)

European
von Willebrand Disease
Community



Steering Committee:



Mariangela Pelligrini

(ERN-EuroBloodNet)



Natacha Bolaños

(ERN-EuroBloodNet ePAGs,
Lymphoma Coalition)



Vincent Ribrag

(Gustave Roussy Hospital,
France)